Colorado has sold over $15B in Cannabis since legalization
The Colorado Department of Revenue released monthly sales data showing $15 billion in sales since 2014, but a steady decline in sales since the pandemic.
The Colorado Department of Revenue (DOR) released a monthly cannabis sales report for August, the latest month available, showing that adult-use and medical cannabis sales surpassed $15 billion.
While the overall picture looks good, sales are actually down during the past few years since peaking during the pandemic, and the downward trend worries some analysts.
The data shows Colorado adult-use and medical cannabis sales reached a total of $15,028,995,376. Since 2016, the state has sold $1-2 billion in cannabis each year. But because of oversupply issues ultimately leading to lower prices, Colorado sales are expected to be lower in 2023 than prior years.
The DOR’s Marijuana Sales Reports summarize total sales made by medical and retail cannabis stores monthly by county. The Marijuana Sales Report has monthly total sales for the state, and the Marijuana Sales by County Report shows monthly sales by medical and adult-use cannabis stores by county.
Adult-use cannabis sales launched in Colorado in January 2014.
Sales are still up compared to when the market launched in 2014, but has fallen precipitously since its peak during the pandemic.
The Colorado cannabis market sold almost $2.2 billion in 2020 and more than $2.2 billion in 2021, as many residents were forced to quarantine at home, and government stimulus checks provided people with some extra cash.
That’s because the state’s dispensaries are struggling amid an economic downturn.
Sales of both medical and adult-use cannabis in Colorado plummeted in June 2022—marking a downward trend that extends to today.
Unless cannabis sales pick up in Q3 of 2023, full-year cannabis sales could be down from 2022, when Colorado cannabis companies sold $1.7 billion in cannabis, matching sales in 2019. As of the end of August, year-to-date sales tallied in at just over $1 billion.
Cannabis Sales in Denver, the State’s Largest Market
In Colorado’s largest city and capital, and the corresponding county, the drop in sales is acute. A July report from the City and County of Denver shows a 22% decline in annual cannabis sales revenue from 2021 to 2022, the largest annual drop since legalization launched.
Consumers who are strapped for cash are buying fewer expensive products, Truman Bradley with the Marijuana Industry Group told 9 News.
“The ripple effect to employees and customers can’t be overstated either,” he said. “As cannabis sales drop, so do the tax revenues.”
Denver makes up about a third of the state’s entire cannabis sales.
“In 2021, 31% of Colorado’s total marijuana sales occurred in the City and County of Denver,” a Municipal Marijuana Management report from 2022 reads. “From 2014 to 2021, the proportion of marijuana sales in Denver out of all Colorado marijuana sales has fallen by 17%, going from 48% to 31%. This downward trend, which has been consistent since the implementation of retail marijuana sales in 2014, indicates marijuana sales growth outside of the City and County of Denver has been increasing faster than within the city.”
A recent report from The Denver Post analyzes the fallout of the post-pandemic cannabis industry in Colorado. “The market’s just bad. It’s bad right now,” cannabis salesperson Val Tonazzi told The Denver Post. “There’s businesses closing, left and right.”
Federal Law Impacts Sales in Colorado
Colorado Gov. Jared Polis recently sent a letter to President Joe Biden on Sept. 5 regarding the U.S. Department of Health and Human Services’ (HHS) recommendation for the Drug Enforcement Administration (DEA) to reschedule cannabis from a Schedule I substance to a Schedule III substance.
“We are pleased to hear that you have recently received Health and Human Services’s (HHS) recommendation to move cannabis to Schedule III,” Polis began in his letter. “It’s about time.”
“This is an historic moment and we owe you and your administration a debt of gratitude for your leadership on catching up with where the science is,” Polis continued.
“Cannabis’ current classification under federal law as a Schedule I drug is contradicted by the scientific evidence. The notion, as previously considered, that cannabis has no accepted medical use, a high potential for abuse, and no accepted safety standards even under medical supervision has been widely disproven, HHS’s recommendation is evidence-based and a move in the right direction.”
Polis also addresses the issues that still need to be resolved, such as banking. He wrote that if cannabis becomes a Schedule III substance, banks would be free to serve cannabis businesses and that tax code 280E would no longer be necessary.
Oversupply, lack of demand, competition with neighboring legal states, and black market sales, puts Colorado cannabis businesses in a bind.
